Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC-WARTS: Gardasil 9 for Difficult-to-treat Palmo-plantar Warts
NCT04814446Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in warts, sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2022; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
warts
Beyond the preview
Go deeper on NCT04814446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814446.